Key Highlights
- Net loss at Palatin Technologies (NASDAQ:PTN) was USD 5.1 million, or USD 1.29 a share, for the quarter ended September 30, 2026, against Net Income of USD 4.7 million a year earlier.
- Revenue fell to USD 0.4 million from USD 8.8 million, as the prior period held the upfront and first milestone payments from Boehringer Ingelheim.
- Research and development rose 34% to USD 3.4 million, with obesity program spending at USD 2.1 million versus USD 1.0 million.
- Cash fell to USD 3.7 million from USD 7.5 million at June 30, and management concluded substantial doubt exists about continuing as a going concern.
Prior-Year Boehringer Payments Make the Comparison Steep
Palatin Technologies (NASDAQ:PTN) filed its Quarterly Report for the three months ended September 30, 2026 on November 16. It is the first quarter of the fiscal year. Revenue was USD 0.4 million compared with USD 8.8 million, and the company swung to a USD 5.1 million net loss from USD 4.7 million of net income. The earlier quarter included roughly EUR 7.5 million, about USD 8.8 million, from the Boehringer Ingelheim retinal disease agreement, covering an upfront payment and a first research milestone. This quarter revenue was only reimbursement for research services under that deal. The company develops melanocortin receptor drugs and now focuses on MC4R agonists for obesity, including rare neuroendocrine conditions such as hypothalamic obesity. Its earlier product, Vyleesi, was sold to Cosette in December 2023, and its dry eye candidate PL9643 was sublicensed in January 2026.
Obesity Program Spending Doubles as IND Work Advances
Research and development expense was USD 3.4 million versus USD 2.5 million. Spending on the obesity programs reached USD 2.1 million, up from USD 1.0 million, on IND-enabling studies for a long-acting peptide and lead optimization for an oral small molecule. Management projects a Phase 1 study for the peptide in the first half of calendar 2027. General and administrative expense rose to USD 2.1 million from USD 1.7 million, mainly on Stock Compensation for executive awards granted in December 2025 and approved by stockholders in July 2026, plus higher professional fees. Operating loss was USD 5.1 million against Operating Income of USD 4.7 million.
USD 3.7 Million of Cash and a Going-Concern Warning
Cash and cash equivalents were USD 3.7 million, down from USD 7.5 million at June 30, 2026, and net cash used in operations was USD 3.7 million versus USD 1.6 million. Total Assets were USD 4.7 million, liabilities USD 2.7 million and stockholders Equity USD 2.0 million, down from USD 6.7 million three months earlier. The accumulated Deficit is USD 472.5 million. Management says it cannot count on future financing under accounting rules and so concluded substantial doubt exists; Options include equity, Debt or cutting planned spending. The company also notes that Nasdaq listing requirements must be met. Boehringer controls development of the licensed retinal program, so milestone timing and amounts are uncertain and can vary widely between reporting periods. The agreement carries potential milestones of up to EUR 280 million, about USD 328 million, plus royalties.
Where Things Stand
The loss is mostly a comparison effect plus rising obesity spending. Palatin Technologies (NASDAQ:PTN) booked USD 8.8 million of Boehringer revenue a year ago and only USD 0.4 million this time, while research costs rose 34%. The larger issue is cash: USD 3.7 million against a quarterly burn of about that size, with going-concern language in the filing. Next markers are new financing, IND progress on the MC4R programs, any Boehringer milestones, and the first-half 2027 study target.


_11_18_2026_14_48_04_195267.jpg)



Please wait processing your request...